CL2013000293A1 - Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc. - Google Patents

Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc.

Info

Publication number
CL2013000293A1
CL2013000293A1 CL2013000293A CL2013000293A CL2013000293A1 CL 2013000293 A1 CL2013000293 A1 CL 2013000293A1 CL 2013000293 A CL2013000293 A CL 2013000293A CL 2013000293 A CL2013000293 A CL 2013000293A CL 2013000293 A1 CL2013000293 A1 CL 2013000293A1
Authority
CL
Chile
Prior art keywords
dry powder
formulation
particles
epoc
phosphodiesterase
Prior art date
Application number
CL2013000293A
Other languages
English (en)
Inventor
Francesca Schiaretti
Daniela Cocconi
Roberto Bilzi
Original Assignee
Chiesi Pharmaceutici S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Pharmaceutici S P A filed Critical Chiesi Pharmaceutici S P A
Publication of CL2013000293A1 publication Critical patent/CL2013000293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación en polvo seco inhalable que comprende como ingrediente activo partículas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y partículas de un vehículo; inhalador de polvo seco y envase que comprende a la formulación, útil para la prevención y/o el tratamiento del asma y epoc.
CL2013000293A 2010-08-03 2013-01-30 Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc. CL2013000293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03

Publications (1)

Publication Number Publication Date
CL2013000293A1 true CL2013000293A1 (es) 2013-05-03

Family

ID=43262631

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000293A CL2013000293A1 (es) 2010-08-03 2013-01-30 Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc.

Country Status (36)

Country Link
US (2) US9132121B2 (es)
EP (2) EP3246016A1 (es)
JP (1) JP6004233B2 (es)
KR (1) KR101805958B1 (es)
CN (2) CN103052379A (es)
AR (1) AR082443A1 (es)
AU (1) AU2011287711B2 (es)
BR (1) BR112013002506A2 (es)
CA (1) CA2807256C (es)
CL (1) CL2013000293A1 (es)
CO (1) CO6690744A2 (es)
CY (1) CY1120605T1 (es)
DK (1) DK2600830T3 (es)
EA (2) EA024922B1 (es)
ES (1) ES2664175T3 (es)
GE (1) GEP20156343B (es)
HR (1) HRP20180717T1 (es)
HU (1) HUE037620T2 (es)
IL (1) IL224517B (es)
LT (1) LT2600830T (es)
MA (1) MA34449B1 (es)
ME (1) ME03022B (es)
MX (1) MX346424B (es)
MY (1) MY179703A (es)
NO (1) NO2600830T3 (es)
NZ (1) NZ606548A (es)
PE (2) PE20130601A1 (es)
PL (1) PL2600830T3 (es)
PT (1) PT2600830T (es)
RS (1) RS57061B1 (es)
SG (1) SG187258A1 (es)
SI (1) SI2600830T1 (es)
TR (1) TR201807012T4 (es)
UA (1) UA112296C2 (es)
WO (1) WO2012016889A2 (es)
ZA (1) ZA201300870B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN106377503A (zh) 2010-08-03 2017-02-08 奇斯药制品公司 包含磷酸二酯酶抑制剂的药物制剂
AU2012266514A1 (en) 2011-06-06 2014-01-09 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN105658629B (zh) 2013-10-22 2019-07-16 奇斯药制品公司 用于制备pde4抑制剂的方法
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EA201692456A1 (ru) * 2014-07-09 2017-08-31 Арвен Иладж Санайи Ве Тиджарет А.Ш. Способ получения составов для ингаляции
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
KR101859752B1 (ko) * 2017-09-13 2018-05-21 심원 조립식 열 저장 운반장치
KR101859750B1 (ko) * 2017-09-13 2018-05-21 제일에스엠피(주) 고정식 열 저장 운반장치
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062007A1 (en) * 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) * 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062006A1 (en) * 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
EP1015895B1 (de) 1997-09-16 2001-07-11 Trench Switzerland AG Spannungsteiler
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP1658872B2 (en) 2002-07-31 2019-08-21 CHIESI FARMACEUTICI S.p.A. Powder inhaler
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DE602006014139D1 (de) * 2005-06-06 2010-06-17 Hoffmann La Roche Sulfonamid-derivate als lebercarnitin-palmitoyl-transferase-hemmer
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN106377503A (zh) 2010-08-03 2017-02-08 奇斯药制品公司 包含磷酸二酯酶抑制剂的药物制剂
AU2012266514A1 (en) 2011-06-06 2014-01-09 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN105658629B (zh) 2013-10-22 2019-07-16 奇斯药制品公司 用于制备pde4抑制剂的方法

Also Published As

Publication number Publication date
JP2013532705A (ja) 2013-08-19
PT2600830T (pt) 2018-04-02
RS57061B1 (sr) 2018-06-29
CN106890165A (zh) 2017-06-27
TR201807012T4 (tr) 2018-06-21
AU2011287711B2 (en) 2016-10-27
EP2600830B1 (en) 2018-02-21
US9132121B2 (en) 2015-09-15
CA2807256A1 (en) 2012-02-09
EA201690541A1 (ru) 2016-07-29
AR082443A1 (es) 2012-12-05
KR20130094784A (ko) 2013-08-26
EP2600830A2 (en) 2013-06-12
ES2664175T3 (es) 2018-04-18
BR112013002506A2 (pt) 2016-05-31
CN103052379A (zh) 2013-04-17
HRP20180717T1 (hr) 2018-07-13
NZ606548A (en) 2015-02-27
US9308200B2 (en) 2016-04-12
EA024922B1 (ru) 2016-11-30
NO2600830T3 (es) 2018-07-21
MA34449B1 (fr) 2013-08-01
AU2011287711A1 (en) 2013-02-21
UA112296C2 (uk) 2016-08-25
GEP20156343B (en) 2015-08-10
EP3246016A1 (en) 2017-11-22
DK2600830T3 (en) 2018-03-12
WO2012016889A2 (en) 2012-02-09
US20120031403A1 (en) 2012-02-09
CA2807256C (en) 2018-08-28
PE20171256A1 (es) 2017-08-28
LT2600830T (lt) 2018-04-10
JP6004233B2 (ja) 2016-10-05
PL2600830T3 (pl) 2018-08-31
ZA201300870B (en) 2014-04-30
KR101805958B1 (ko) 2017-12-07
HUE037620T2 (hu) 2018-09-28
MX2013001172A (es) 2013-03-07
US20150342936A1 (en) 2015-12-03
MY179703A (en) 2020-11-11
ME03022B (me) 2018-10-20
CO6690744A2 (es) 2013-06-17
MX346424B (es) 2017-03-21
SG187258A1 (en) 2013-03-28
PE20130601A1 (es) 2013-05-30
IL224517B (en) 2018-04-30
CY1120605T1 (el) 2019-12-11
WO2012016889A3 (en) 2012-04-19
SI2600830T1 (en) 2018-05-31
EA027692B1 (ru) 2017-08-31
EA201390049A1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
CL2013000293A1 (es) Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc.
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
PH12017501306A1 (en) Inhibitors of histone demethylases
HRP20190164T1 (hr) Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2014000113A1 (es) Compuestos derivados de quinolinas sustituidas; formulacion farmaceutica que los contiene; y su uso para el tratamiento de una enfermedad que se puede tratar mediante la inhibicion de la enzima syk, tales como rinitis alergica, asma, epoc, bronquitis, lupus eritematoso, esclerosis multiple, osteoporosis, osteopenia y arterioesclerosis.
GT201400090A (es) 2-tiopirimidinonas
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
EP2799082A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORAL DISEASES OR ASTHMA CONTAINING A STOREM STEREMIA OVALIFOLIA EXTRACT OR A FRACTION OF IT AS AN ACTIVE SUBSTANCE
EP3037091A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
MX2016000116A (es) Formulaciones de compuestos organicos volatiles que tienen actividad antimicrobiana.
MX2015004316A (es) Formulacion de aroma y fragancia (iv).
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders
TR201000624A2 (tr) Tiotropium ve flutikazon içeren kuru toz formundaki farmasötik kompozisyon.
CU20100090A7 (es) Formulaciones de polvo seco que comprenden derivados del ácido ascórbico
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TR201000621A2 (tr) Tiotropium ve budesonid içeren kuru toz formundaki farmasötik kompozisyon
TR201000731A2 (tr) Tiotropyum ve flutikazon içeren kuru toz formundaki farmasötik kompozisyon.
TR201000682A2 (tr) Formoterol ve flutikazon içeren farmasötik preparatlar.
TR201000619A2 (tr) Tiotropium ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.